This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 1996 Oct 15;40(8):804-6.

doi: 10.1016/0006-3223(96)00250-8.

Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients

H J van Megen¹, H G Westenberg, J A den Boer

Affiliations

PMID: 8894076
DOI: 10.1016/0006-3223(96)00250-8

Clinical Trial

Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients

H J van Megen et al. Biol Psychiatry. 1996.

. 1996 Oct 15;40(8):804-6.

doi: 10.1016/0006-3223(96)00250-8.

Authors

H J van Megen¹, H G Westenberg, J A den Boer

Affiliation

¹ Rudolf Magnus Institute for Neurosciences, Department of Psychiatry, University Hospital Utrecht, The Netherlands.

PMID: 8894076
DOI: 10.1016/0006-3223(96)00250-8

No abstract available

PubMed Disclaimer

Similar articles

A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.
Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Chenault A, Shrivastava R, Matzura-Wolfe D, Lines C, Reines S. Kramer MS, et al. Biol Psychiatry. 1995 Apr 1;37(7):462-6. doi: 10.1016/0006-3223(94)00190-E. Biol Psychiatry. 1995. PMID: 7786960 Clinical Trial.
Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic.
Cowley DS, Adams JB, Pyke RE, Cook J, Zaccharias P, Wingerson D, Roy-Byrne PP. Cowley DS, et al. Biol Psychiatry. 1996 Sep 15;40(6):550-2. doi: 10.1016/0006-3223(96)00163-1. Biol Psychiatry. 1996. PMID: 8879478 Clinical Trial. No abstract available.
Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
Pols H, Verburg K, Hauzer R, Meijer J, Griez E. Pols H, et al. Biol Psychiatry. 1996 Nov 1;40(9):913-7. doi: 10.1016/0006-3223(95)00494-7. Biol Psychiatry. 1996. PMID: 8896779 Clinical Trial.
Cholecystokinin and panic disorder: past and future clinical research strategies.
Bradwejn J, Koszycki D. Bradwejn J, et al. Scand J Clin Lab Invest Suppl. 2001;234:19-27. Scand J Clin Lab Invest Suppl. 2001. PMID: 11713976 Review.
[Cholecystokinin antagonists: anxiolytic drugs of the future].
Bourin M, Bradwejn J. Bourin M, et al. Pathol Biol (Paris). 1992 Mar;40(3):215-7. Pathol Biol (Paris). 1992. PMID: 1608663 Review. French. No abstract available.

See all similar articles

Cited by

The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.
van Megen HJ, Westenberg HG, den Boer JA, Slaap B, van Es-Radhakishun F, Pande AC. van Megen HJ, et al. Psychopharmacology (Berl). 1997 Feb;129(3):243-8. doi: 10.1007/s002130050186. Psychopharmacology (Berl). 1997. PMID: 9084062 Clinical Trial.
Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.
Shlik J, Vasar E, Bradwejn J. Shlik J, et al. CNS Drugs. 1997 Aug;8(2):134-52. doi: 10.2165/00023210-199708020-00005. CNS Drugs. 1997. PMID: 23338219
Experimental panic provocation in healthy man-a translational role in anti-panic drug development?
Kellner M. Kellner M. Dialogues Clin Neurosci. 2011;13(4):485-93. doi: 10.31887/DCNS.2011.13.4/mkellner. Dialogues Clin Neurosci. 2011. PMID: 22275853 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information